Search
Influenza A virus A/Darwin/6/2021 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16922ApprovedThe influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB16925ApprovedWithdrawnThe influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Synonyms: Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (UV, formaldehyde inactivated)Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB18661ApprovedThe influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/Sydney/1304/2022 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB19321ApprovedThe influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/Massachusetts/18/2022 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB19322ApprovedWithdrawnThe influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB19323ApprovedWithdrawnThe influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/Thailand/8/2022 IVR-237 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB19324ApprovedWithdrawnThe influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Synonyms: Influenza A virus A/Thailand/8/2022 IVR-237 antigen (UV, formaldehyde inactivated)Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole
go.drugbank.com/drugs/DB19413ApprovedThe influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
KD7040
go.drugbank.com/drugs/DB05214InvestigationalIt is being developed by Kalypsys. … KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.
Pilaralisib
go.drugbank.com/drugs/DB11772InvestigationalPilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).